The lawsuit also argues that Zepbound has been proven to be more effective for weight loss, and, on its formulary page for the switch, CVS acknowledges that studies with that implication exist while saying "real-world evidence suggests the two are comparable." "Because of their different methods of action, different clinical outcomes, and different side effects for individual patients, Zepbound and Wegovy are not clinically interchangeable," the plaintiffs said in their complaint

National Health and Nutrition Examination Survey (NHANES) 20212023 data are available from the National Center for Health Statistics at Korea National Health and Nutrition Examination Survey (KNHANES) 20212023 raw datasets can be accessed and downloaded from the Korea Disease Control and Prevention Agency (KDCA) data portal after user registration and agreement to the data use policy: General information in English is available at Clinical trial data are available from the Aggregate Analysis of ClinicalTrials.gov (AACT) database, maintained by the Clinical Trials Transformation Initiative (CTTI), at As AACT is updated daily, the dataset used in this study was restricted to trials with information posted through 2020
These patients often experience multiple comorbidities, such as diabetes and cardiovascular disease, where GLP-1 therapies offer additional health benefits beyond weight loss
Researchers are still unsure as to the causes of essential blepharospasm
While surgery can relieve symptoms, patients may still face long-term neurological effects, such as cognitive difficulties or seizures, depending on the tumors location and size